TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01288274

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community Based administration of DMPA
Description: Injectable contraceptive administered by clinic based health extension worker or community based reproductive health agent using same protocol to test equivalence of community based distribution to facility based distribution
Study: NCT06665503

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc Supplement, probiotic
Description: received oral zinc supplementation; 2.5 ml every 12 hours for children aged \<1 year and 5 ml every 12 hours for older children; the probiotics group received oral probiotics; 1 probiotic sachet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc Supplement, probiotic
Description: received oral zinc supplementation; 2.5 ml every 12 hours for children aged \<1 year and 5 ml every 12 hours for older children; the probiotics group received oral probiotics; 1 probiotic sachet
Study: NCT06613633

Intervention type: DRUG
Intervention: third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)
Description: Patients with advanced EGFR-mutated NSCLC who met the inclusion criteria and received third-generation EGFR-TKI (monotherapy or combined with brain radiotherapy)
Study: NCT02258438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Uninterrupted sitting
Description: Subjects will be asked to refrain for two days from any structured activity and to reduce any daily life activity (walking, taking the stairs, biking, etc.) in their daily life. On day 3, subjects will remain seated all day in the room calorimeter, except to rise from the chair to void.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting + 1 bout of activity
Description: Subjects will be asked to perform 45 minutes of moderate-exercise in the morning once per day for two days in their daily life. On day 3 they will remain seated all day in the room calorimeter, except to rise from the chair to void, and to perform one bout of 45-min moderate-intensity (defined below) walking on a treadmill at 1000.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting + microbursts of activity
Description: Subjects will be asked to refrain from any structured exercise for two days but to walk for 5 minutes each hour between 1000 and 1800 in daily life. On day 3, subjects will rise from the seated position every hour for 9 hours from 1000 to 1800 to complete 5min moderate-intensity (defined below) walking on a treadmill, which represents a total of 45min.
Study: NCT00704418

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sterile ophthalmic solution
Study: NCT02437799

Intervention type: OTHER
Intervention: Dicrotic wave analysis
Description: We will download data from the pulse oximeter that is being used to monitor the patient during their surgery.
Study: NCT02220907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin/Canagliflozin
Description: Co-administration of Teneligliptin and Canagliflozin orally once daily for 52 weeks.
Study: NCT03410953

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed).
Description: The primary immunisation consists of 4 separate 0.5 ml doses administered at the following schedule:~1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine
Study: NCT02382406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 6 IV, D1 for 4 cycles (cycle = 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 6 IV, D1 for 4 cycles (cycle = 21 days)
Study: NCT04477187

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal Handpiece
Description: Radiofrequency (RF) will travel through the RF generator through the electrodes and into the dermal layer beneath the surface of the skin. The microneedles of the dermal cartridges coupled with the thermal heat will stimulate neocollagenesis and neoelastosis, aiding in the reduction of submental laxity.
Study: NCT01424930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Participants will receive abiraterone acetate at a starting dose of 1,000 mg once daily for 7 days post 30-minutes of a standardized low-fat meal and high-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Participants will receive abiraterone acetate at a starting dose of 1,000 mg once daily for 7 days post 30-minutes of a standardized low-fat meal and high-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.
Study: NCT02449668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture techniques with a plastic insertion tube was used to introduce every needle. The needles were perpendicularly inserted to a depth of 2-3 cm. The needles were applied to the area of the injured shoulder while the patient was lying in a lateral decubitus position on the stretcher. The skin was prepared with clorhexidine and the needles were sterile. They measured 40 mm long and 0.25 mm in diameter. The sessions lasted 20 minutes and the Qi sensation was sought by consistent manipulations, with rotation of the needles in both senses and scratching of the handle.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Study: NCT00808574

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea screening intervention
Description: Brief, theory-based, online assessment of OSA risk followed by risk-tailed OSA presentation.
Study: NCT04156165

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VLCD-Active
Description: Lighter life formula products supplied to subjects, four sachets pr day. Dietetic advise given regularly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maintenance-Active
Description: Weight loss maintenance diet with high protein and low glycemic index and load, high in fiber and whole grain, daily including 150 g minced beef.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VLCD-Control
Description: Lighter life VLCD products

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance-Control
Description: Weight loss maintenance diet with moderate protein and low glycemic index and load, high in fiber and whole grain, daily including 25 g minced beef.
Study: NCT01791920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A(Botulax®)
Description: Single administration, Day 0, 20 units

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A(Botox®)
Description: Single administration, Day 0, 20units
Study: NCT02273830

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxygen
Description: Oxygen administered after adjustment during a waking test or at 3L/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxygen
Description: Oxygen administered after adjustment during a waking test or at 3L/min
Study: NCT02417779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Description: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Description: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Description: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Description: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Description: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Description: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Description: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Description: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Description: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Description: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Description: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Description: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Study: NCT01916655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Management Care
Description: Provision of sleep apnea-specific self-management education and support for those who are prescribed CPAP therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Management Mobile Care
Description: Provision of sleep apnea-specific self-management education and support for those who are prescribed CPAP therapy via mobile phone

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: standard and typical CPAP educational and support protocol; is the base level education and support that is provided in the other two interventions in this study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: standard and typical CPAP educational and support protocol; is the base level education and support that is provided in the other two interventions in this study.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: standard and typical CPAP educational and support protocol; is the base level education and support that is provided in the other two interventions in this study.
Study: NCT00426608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metyrapone
Description: Metyrapone will be available as 250 mg dose capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metyrapone
Description: Metyrapone will be available as 250 mg dose capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metyrapone
Description: Metyrapone will be available as 250 mg dose capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metyrapone
Description: Metyrapone will be available as 250 mg dose capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metyrapone
Description: Metyrapone will be available as 250 mg dose capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alprazolam
Description: Alprazolam capsules will be available with dose strength of 0.25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alprazolam
Description: Alprazolam capsules will be available with dose strength of 0.25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alprazolam
Description: Alprazolam capsules will be available with dose strength of 0.25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alprazolam
Description: Alprazolam capsules will be available with dose strength of 0.25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alprazolam
Description: Alprazolam capsules will be available with dose strength of 0.25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: GSK561679 placebo tablets visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that visually matches active Alprazolam capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: GSK561679 placebo tablets visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that visually matches active Alprazolam capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: GSK561679 placebo tablets visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that visually matches active Alprazolam capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: GSK561679 placebo tablets visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that visually matches active Alprazolam capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: GSK561679 placebo tablets visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that visually matches active Alprazolam capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK561679
Description: GSK561679 tablets will be available with dose strength of 50, 10 and 200 mg.
Study: NCT04107493

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Portable Oxygen Cylinder
Description: A POC is a medical device that is indicated for patients who require supplemental oxygen, including COPD patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobi
Description: ResMed's variant of POC
Study: NCT02686840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sublingual misoprostol
Description: All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~* Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose).~* Paracetamol, eight hourly, will be provided as analgesic or antipyretic.~* A specimen bottle to collect the POC if passed out.~* Two pairs of disposable gloves.~* Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal misoprostol
Description: All patients will receive three doses of vaginal misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~Paracetamol, eight hourly, will be provided as analgesic or antipyretic
Study: NCT02999464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qigong
Description: The experimental group will be required to practice a total of 50 minutes of qigong training 3 times per week and for 16 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fitness exercise
Description: Active control group will be required to practice a total of 50 minutes of fitness training 3 times per week and for 16 weeks
Study: NCT00511563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW876008 and GSK561679
Description: GW876008 and GSK561679
Study: NCT00426608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK561679
Description: GSK561679 tablets will be available with dose strength of 50, 10 and 200 mg.
Study: NCT04043520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: GnRH antagonist will be given once for premenopausal women (12-week intervention) and twice for postmenopausal women (24-week intervention)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: GnRH antagonist will be given once for premenopausal women (12-week intervention) and twice for postmenopausal women (24-week intervention)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen Product
Description: Estrogen patches will be worn by those randomized to the Estradiol arms in both premenopausal and postmenopausal groups. Patches will be applied weekly and will be worn for the for entirety of the intervention (12 or 24 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo estradiol
Description: Placebo patches will be worn by those randomized to the placebo arms in both premenopausal and postmenopausal groups. Patches will be applied weekly and will be worn for the for entirety of the intervention (12 or 24 weeks).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo estradiol
Description: Placebo patches will be worn by those randomized to the placebo arms in both premenopausal and postmenopausal groups. Patches will be applied weekly and will be worn for the for entirety of the intervention (12 or 24 weeks).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo GnRH antagonist
Description: Postmenopausal women randomized to the placebo injection arm will receive two placebo drug injections of normal saline (24-week intervention)
Study: NCT04272359

Intervention type: DRUG
Intervention: Sulfa-zero: possible benefits of the treatment of new generation hypoglycaemic drugs compared to sulphonylureas
Description: Substitution of sulfonylureas with other classes of new hypoglycaemic drugs. In every group, it will be evaluated:~* efficacy in terms of glycometabolic compensation (glycemia, HbA1c, lipid profile);~* effects on BMI, blood pressure monitoring and hypoglycemic risk;~* changes in renal function and microalbuminuria;~* tolerability and side effects of the new therapeutic regimes;~* therapeutic adherence;~* post-prandial glycemic excursion, determined by a 6-point glycemic diary (pre- and 2h post-prandial glucose values) to be performed at home in the week before the scheduled follow-up visit;~* effects on chronic complications of diabetes and cardiovascular safety.

Intervention type: DRUG
Intervention: Sulfa-zero: possible benefits of the treatment of new generation hypoglycaemic drugs compared to sulphonylureas
Description: Substitution of sulfonylureas with other classes of new hypoglycaemic drugs. In every group, it will be evaluated:~* efficacy in terms of glycometabolic compensation (glycemia, HbA1c, lipid profile);~* effects on BMI, blood pressure monitoring and hypoglycemic risk;~* changes in renal function and microalbuminuria;~* tolerability and side effects of the new therapeutic regimes;~* therapeutic adherence;~* post-prandial glycemic excursion, determined by a 6-point glycemic diary (pre- and 2h post-prandial glucose values) to be performed at home in the week before the scheduled follow-up visit;~* effects on chronic complications of diabetes and cardiovascular safety.
Study: NCT00426608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK561679
Description: GSK561679 tablets will be available with dose strength of 50, 10 and 200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK561679
Description: GSK561679 tablets will be available with dose strength of 50, 10 and 200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK561679
Description: GSK561679 tablets will be available with dose strength of 50, 10 and 200 mg.
Study: NCT02864225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scalp electrode,
Description: the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetal doppler
Description: the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUM
Description: the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler